Les documentations contenus dans cette section d’archives sont fournis à des fins historiques uniquement. Les renseignements contenus dans chaque documentation ne sont exacts qu’à la date de leur publication originale respective. NOXXON rejette toute obligation de mise à jour des renseignements contenus dans ces documentations après leur date de publication.

2019, Février 18 - Lettre aux Actionnaires

Présentations
2020, Juillet - Présentation investisseurs
2019, September 30 - Webcast: ESMO Congress 2019 Poster Presentation
  -download poster
  -download presentation
  -view webinar recording
2019, September 23 - Webinar: What’s next in treatment of brain cancer patients? Testing NOX-A12 with Radiotherapy in a Phase 1/2 Clinical Trial
  -download presentation
  -download draft script
  -view webinar recording
2018, Septembre - Présentation KOL Event GBM
2018, Septembre - Présentation EquityForum Fall Conference
2018, Mai - Présentation ASCO
2018, Mai - Présentation Bio€quity

Managers Transactions (as disclosed by company to competent authority)
2020, Juillet 30 - Transactions related to grant of stock options to Aram MangasarianOscar Izeboud
2020, Avril - Sale of shares effective 17 April 2020, Donald deBethizy
2019, Octobre 09 - Transactions related to grant of stock options to Aram Mangasarian, Donald deBethizy
2019, Août -Transaction related to Aug 2019 private placement, share purchases effective 15 Aug 2019: Aram Mangasarian
2019, Juillet -Transactions related to July 2019 rights issue, share purchases effective 23 July 2019: Donald deBethizy (second)
2019, Juillet -Transactions related to July 2019 rights issue, share purchases effective 23 July 2019: Aram Mangasarian
2019, Juillet -Transactions related to July 2019 rights issue, share purchases effective 23 July 2019: Donald deBethizy (first)

2017, Juillet 11 - NOXXON Pharma NV Prospectus approved 10 July 2017 (Anglais) Résumé du Prospectus en français

Overview and Characteristics of the Convertible Bonds of the financing agreement published on April 23 2020
2020, Juin 17 - Overview of the Convertible Bonds 
2020, Avril 23 - Characteristics of the Convertible Bonds 
2020, Avril 23 - Press release

Terms of the Warrants of the financing agreement signed on November 15, 2018
2020, Avril 17 - Overview of the Warrants
2018, Novembre 16 - Terms of the Warrants
2018, Novembre 16 - Press release

Overview and Characteristics of the Convertible Notes listed on Euronext Access Paris in Sept 2018
2018, Décembre 11 - Overview of the Outstanding Notes Listed on Euronext Access Paris - NOXXON7%PT
2018, Novembre 16 - Issuer conversion notices submitted on November 16, 2018
2018, Septembre - Terms and Conditions
2018, Septembre - Euronext Listing Announcement
2018, November 16 - Press release
2018, Septembre 19 - Press release

Overview and Characteristics of the Notes and Warrants of the financing agreement signed on May 01, 2017
2020, Juin 17 - Updated Summary Table of ODIRNANE & BSA
2017, Mai 02 - Characteristics of the Warrants
2017, Mai 02 - Characteristics of the Notes

2020, Avril 22 - 2019 Annual Report (Corrected version: contains corrected date of  signature of the audit opinion, and no other changes.)
2020, Avril 22 - 2019 Annual Report
2019, Avril 12 - 2018 Annual Report
2018, Avril 30 - 2017 Annual Report
2017, Juin 07 - 2016 Annual Report - statutory
2017, Avril 30 - 2016 Annual Report - non statutory

2016, Décembre 07 - 2015 NOXXON Pharma N.V. IFRS

2019, Half-Year Financial Report as of 30 June 2019
2018, Half-Year Financial Report as of 30 June 2018
2017, Half-Year Financial Report as of 30 June 2017
2017, Octobre 30 - Condensed consolidated interim financial statements as of 30 June 2017
2016, Octobre 31 - Condensed consolidated interim financial statements as of 30 June 2016

2016, Septembre 28 - Information Document